BiotechTube

TSC-204-A0201 + TSC-204-C0702 + TSC-200-A0201 + TSC-204-A0201 + TSC-204-C0702 + TSC-204-A0201 + TSC-200-A0201 + TSC-204-C0702 + TSC-200-A0201 + TSC-204-A0201 + TSC-203-A0201 + TSC-204-C0702 + TSC-203-A0201 + TSC-200-A0201 + TSC-203-A0201 + TSC-203-A0201 + TSC-204-A0101 + TSC-201-B0702 + TSC-204-A0201 + TSC-204-A0101 + TSC-204-A0201 + TSC-201-B0702 + TSC-204-C0702 + TSC-204-A0101 + TSC-204-C0702 + TSC-201-B0702 + TSC-200-A0201 + TSC-204-A0101 + TSC-200-A0201 + TSC-201-B0702 + TSC-203-A0201 + TSC-204-A0101 + TSC-203-A0201 + TSC-201-B0702 + TSC-202-A0201 + TSC-204-A0201 + TSC-202-A0201 + TSC-204-C0702 + TSC-202-A0201 + TSC-200-A0201 + TSC-202-A0201 + TSC-203-A0201 + TSC-202-A0201 + TSC-204-A0101 + TSC-202-A0201 + TSC-201-B0702 + TSC-202-A0201

Phase 1Active
0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Head and Neck Cancer

Conditions

Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma

Trial Timeline

May 6, 2024 → Dec 30, 2026

NCT ID
NCT05973487

About TSC-204-A0201 + TSC-204-C0702 + TSC-200-A0201 + TSC-204-A0201 + TSC-204-C0702 + TSC-204-A0201 + TSC-200-A0201 + TSC-204-C0702 + TSC-200-A0201 + TSC-204-A0201 + TSC-203-A0201 + TSC-204-C0702 + TSC-203-A0201 + TSC-200-A0201 + TSC-203-A0201 + TSC-203-A0201 + TSC-204-A0101 + TSC-201-B0702 + TSC-204-A0201 + TSC-204-A0101 + TSC-204-A0201 + TSC-201-B0702 + TSC-204-C0702 + TSC-204-A0101 + TSC-204-C0702 + TSC-201-B0702 + TSC-200-A0201 + TSC-204-A0101 + TSC-200-A0201 + TSC-201-B0702 + TSC-203-A0201 + TSC-204-A0101 + TSC-203-A0201 + TSC-201-B0702 + TSC-202-A0201 + TSC-204-A0201 + TSC-202-A0201 + TSC-204-C0702 + TSC-202-A0201 + TSC-200-A0201 + TSC-202-A0201 + TSC-203-A0201 + TSC-202-A0201 + TSC-204-A0101 + TSC-202-A0201 + TSC-201-B0702 + TSC-202-A0201

TSC-204-A0201 + TSC-204-C0702 + TSC-200-A0201 + TSC-204-A0201 + TSC-204-C0702 + TSC-204-A0201 + TSC-200-A0201 + TSC-204-C0702 + TSC-200-A0201 + TSC-204-A0201 + TSC-203-A0201 + TSC-204-C0702 + TSC-203-A0201 + TSC-200-A0201 + TSC-203-A0201 + TSC-203-A0201 + TSC-204-A0101 + TSC-201-B0702 + TSC-204-A0201 + TSC-204-A0101 + TSC-204-A0201 + TSC-201-B0702 + TSC-204-C0702 + TSC-204-A0101 + TSC-204-C0702 + TSC-201-B0702 + TSC-200-A0201 + TSC-204-A0101 + TSC-200-A0201 + TSC-201-B0702 + TSC-203-A0201 + TSC-204-A0101 + TSC-203-A0201 + TSC-201-B0702 + TSC-202-A0201 + TSC-204-A0201 + TSC-202-A0201 + TSC-204-C0702 + TSC-202-A0201 + TSC-200-A0201 + TSC-202-A0201 + TSC-203-A0201 + TSC-202-A0201 + TSC-204-A0101 + TSC-202-A0201 + TSC-201-B0702 + TSC-202-A0201 is a phase 1 stage product being developed by TScan Therapeutics for Head and Neck Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05973487. Target conditions include Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma.

What happened to similar drugs?

11 of 20 similar drugs in Head and Neck Cancer were approved

Approved (11) Terminated (0) Active (9)
✅Galcanezumab-GnlmEli LillyApproved
✅Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy]AbbVieApproved
✅Placebo + Zolmitriptan + Zolmitriptan + ZolmitriptanAstraZenecaApproved
✅Propranolol or nadolol + Placebo control + Optimal Acute TherapyMerckApproved
✅Pembrolizumab + Carboplatin + PaclitaxelMerckApproved
✅Erenumab 70 mg + Erenumab 140 mg + PlaceboAmgenApproved
✅Rimegepant + ZavegepantPfizerApproved

Hype Score Breakdown

Clinical
6
Activity
12
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05973487Phase 1Active

Competing Products

20 competing products in Head and Neck Cancer

See all competitors
ProductCompanyStageHype Score
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 3
37
DFN-15 ActiveDr. Reddy's LaboratoriesPhase 3
37
Ha44 Gel 0.74% w/wDr. Reddy's LaboratoriesPhase 2
32
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 3
37
Abametapir Lotion 0.74% w/wDr. Reddy's LaboratoriesPhase 1
26
DFN-11 InjectionDr. Reddy's LaboratoriesPhase 2
24
Abametapir Lotion 0.74% w/w + Sodium Lauryl Sulfate + Saline 0.9% + PlaceboDr. Reddy's LaboratoriesPhase 1
26
Abametapir Lotion 0.74% w/w + Vehicle LotionDr. Reddy's LaboratoriesPhase 2
32
Ha44 GelDr. Reddy's LaboratoriesPhase 2
32
AFM24 + SNK01AffimedPhase 1/2
14
Cemiplimab + CetuximabEli LillyPhase 2
42
BB-401Benitec BiopharmaPhase 2
25
Placebo + LY2300559Eli LillyPhase 2
27
Gemcitabine + ACR-368Acrivon TherapeuticsPhase 2
32
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
17
Ramucirumab + PembrolizumabEli LillyPhase 2
39
Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + CetuximabBioAtlaPhase 2
25
Patritumab + Cetuximab + Cisplatin + Carboplatin + PlaceboDaiichi SankyoPhase 2
27
Patritumab + Cetuximab + Cisplatin + CarboplatinDaiichi SankyoPhase 1
29
cevimeline hydrochlorideDaiichi SankyoPhase 3
40